Breaking News on Global Pharmaceutical Technology & Manufacturing

Headlines > All Ingredients News

GMP assessments should consider environmental impact say campaigners

06-Jul-2015 - A group calling for GMP assessments to consider the environmental impact of API production says pollution generated by suppliers in China is furthering the spread of resistant superbugs.

ICH clarifies Q7 guidance on API GMP manufacturing

30-Jun-2015 - In response to a flood of requests over uncertainties regarding ICH Q7 guidance, the international consortium recently released a question and answer  (Q&A) document intended help companies implement appropriate GMPs (good manufacturing practices) at all stages of the API supply chain.

Health Canada asks importers to quarantine Polydrug APIs over data concerns

29-Jun-2015 - Canada has asked importers to quarantine APIs made by India’s Polydrug Laboratories over concerns about its manufacturing plant in Ambarnath in Maharashtra.

Saneca buys Europe's only independent, US FDA approved Beta-lactams plant

25-Jun-2015 - API firm Saneca Pharmaceuticals has acquired struggling drug formulator Suir Pharma Ireland in a deal with former owner Mutares AG.

News in brief

Thermo Fisher will pay £256m for Alfa Aesar

25-Jun-2015 - Thermo Fisher Scientific has anncouned plans to buy research chemicals firm Alfa Aesar from Johnson Matthey for £256m ($405m).

UK scientists discover key poppy alkaloid production enzyme

25-Jun-2015 - GSK and UK academics claim a newly identified enzyme is the missing link in the mechanism poppies use to make painkilling alkaloids like morphine and codeine and the anticancer compound noscapine.

New nanotech excipient makes for better delayed-release drugs say researchers

22-Jun-2015 - Swedish scientists who developed the solubility enhancing nanotech excipient Upsalite say it can also be used to improve delayed release formulations.

ScinoPharm to make API for Chinese drugmaker eyeing US celecoxib market

22-Jun-2015 - Raffles PharmaTech has contracted ScinoPharm to make the API for a generic version of the arthritis pain drug celecoxib being developed for the US market.

Slovenian regulators slam Polydrug API plant in India

17-Jun-2015 - Polydrug Laboratories chose not to log customer complaints about APIs made at its plants in Maharashtra according to Slovenian regulators.

API plant inspections to continue despite rule change say South African regulators

15-Jun-2015 - South African regulators will continue to inspect all local and some international API sites despite relaxing facility assessment rules last week.

Nucleation knowhow can aid API makers say crystal experts due to meet in France

10-Jun-2015 - Crystallisation experts from across Europe will meet in France this month to share ideas and research that will shape how APIs are made in the future.

Johnson Matthey: Ageing population and generics will drive API biz; Alfa Aesar sale on track

08-Jun-2015 - Johnson Matthey saw revenue from (active pharmaceutical ingredients) APIs increase in fiscal 2015 despite competition from generic manufacturers and the relocation of a key customer. 


The age of phage? World first cGMP certification for phage therapy plant

03-Jun-2015 - AmpliPhi Biosciences’ phage-based antibacterial therapies plant in Ljubljana has been deemed to meet manufacturing standards by Slovenian regulators.

US preference for ANSI 363 excipient standards will change, says EXCiPACT

03-Jun-2015 - Multinational excipient-makers will drive US interest in EXCiPACT, the industry-led certification scheme says as a UK Colorcon plant becomes the eighteenth site to receive accreditation.

$100m API investment a boost to Gilead's in-house capacity

28-May-2015 - Sovaldi maker Gilead Sciences has opened a new laboratory and is investing a further $100m (€91m) for API manufacturing at its site in Canada.

April US chemical output for pharma down says ACC; SOCMA welcomes R&D tax credit move

27-May-2015 - US production of chemicals for the drug industry fell in April according to data released days after renewed calls for permanent tax breaks to help American manufacturers compete globally.

Lonza set to get commercial Adva-27a contract if cancer drug is approved

27-May-2015 - Lonza shipped a sample batch of a drug for resistant cancers this week and is set produce commercial supplies if the Phase I candidate goes on to be approved says Sunshine Biopharma. 

Grace: silica gel plant certification will cut customer audit burden

26-May-2015 - WR Grace says certification for its excipient plant in Germany will reduce the audit burden faced by drug industry customers.

Home-brew morphine: Is opiate production about to get way too easy?

21-May-2015 - Access to yeast strains modified to produce opiates for cheaper, more effective pain meds must be strictly controlled according to researchers who warn that stopping criminals using such API manufacturing routes to make illegal narcotics is vital.

European freeze-drying market heats up: Symbiosis invests citing high demand

19-May-2015 - Symbiosis Pharmaceutical Services has launched a bulk freeze drying offering for APIs and intermediates, citing new contracts as a driver for the investment.

Dr Reddy’s yen for growth: Indian generics and API firm plans to partner in Japan

18-May-2015 - Dr Reddy’s has set out to build in the Japanese market days after revealing that higher generic and API sales elsewhere had been pegged back by currency fluctuations.

SAFC expands ADC and bulk drug manufacturing in CA, MO

13-May-2015 - SAFC has announced investments in gene therapy manufacturing sites in Missouri and California.

Nisso opens expanded HPC plant on back of pharma demand

11-May-2015 - Recent US FDA approval of products containing the excipient HPC has driven demand, according to Nippon Soda (Nisso) which has expanded its production facility in Japan.

Siegfried set to buy custom synthesis and API units from BASF for $300m

07-May-2015 - BASF says it remains committed to the pharma industry despite plans to divest its custom synthesis business and around 100 APIs and intermediates to Siegfried Holding.

Study finds targeting HDAC enzymes could offer hope against Alzheimer’s

06-May-2015 - A new study is shaking up ideas about a known therapeutic strategy for Alzheimer’s disease, following a discovery by scientists at Scripps Research Institute testing enzyme inhibitors.

Key Industry Events


Access all events listing

Our events, Shows & Conferences...